Open Nav

Dendreon Pharmaceuticals LLC

  • Jim Caggiano, Dendreon Pharmaceuticals LLC

Highlight the successful commercialization of autologous cell therapies

  • Date:Thursday, October 18
  • Time:11:15 AM - 11:30 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 30,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease.
  • Company Website:https://www.dendreon.com/
  • Company HQ City:Seal Beach
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Jim Caggiano, Chief Executive Officer
  • Year Founded:1997
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :N/A
  • Development Phase of Primary Product:Other/Not Applicable
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :N/A
  • Additional Information/Comments:Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, has overcome numerous obstacles during its history. Despite a rocky past, Dendreon recently underwent a remarkable turnaround, successfully shifting its commercial strategy and reinvigorating sales of its revolutionary flagship product, PROVENGE® (sipuleucel-T) – a treatment for advanced prostate cancer and the first FDA-approved immunotherapy made from a patient’s own immune cells. Starting with Dendreon’s sale to Sanpower Group in 2017, there has been no stopping Dendreon over the past year as it brings PROVENGE to more men living with advanced prostate cancer. To date, PROVENGE has been prescribed to more than 30,000 patients. As other cell therapies navigate the move from clinical promise to commercial success, much can be learned from Dendreon about the complexities of manufacturing and delivering autologous cell therapies.
  • Previous and Current Investors:N/A
  • Size of Last Investment Round:N/A
  • Total Amount Raised to Date, In All Rounds:N/A
Speakers
Jim Caggiano
Dendreon Pharmaceuticals LLC
Back